Results 221 to 230 of about 690,240 (260)
Some of the next articles are maybe not open access.

Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease

European Urology, 2019
The category "BCG-unresponsive disease", formulated by experts at the request of the United States Food and Drug Administration, denotes a group of patients with recurrent non-muscle-invasive bladder cancer for whom continued BCG treatment is unlikely to provide benefit.
Neema Navai   +7 more
openaire   +3 more sources

New cancer breakthrough therapies at the United States Food and Drug Administration

Journal of Hospital Management and Health Policy, 2018
Cancer is an emotive word that strikes fear into many people. This is hardly surprising since premature death due to cancer is the leading cause of mortality in Canada, the United States and many other countries.
openaire   +2 more sources

The United States Food and Drug Administration Paradigm for the Regulation of Tissue-Engineered Products

Tissue Engineering, 1997
As tissue engineering products are evolving, so too are the regulatory approaches to these products. Tissue engineering product development for the United States market is facilitated by an understanding of how the U.S. Food and Drug Administration (FDA) regulates tissue engineering products.
Thomas L. Eggerman, Amy P. Patterson
openaire   +2 more sources

Autologous Cultured Chondrocytes: Adverse Events Reported to the United States Food and Drug Administration

The Journal of Bone and Joint Surgery (American), 2006
Carticel is an autologous cultured chondrocyte product that has been approved by the United States Food and Drug Administration for the repair of symptomatic cartilaginous defects of the femoral condyle that are caused by acute or repetitive trauma in patients who have been previously managed with arthroscopy or other surgical procedures.
Jacquelyn A. Polder   +7 more
openaire   +3 more sources

An Overview of How the Food and Drug Administration Regulates New Drug Development in the United States

Drug Information Journal, 1996
The way in which the Food and Drug Administration (FDA) regulates new drug development is covered. Each stage—clinical studies, the new drug application, after approval of the new drug application —is described in detail. A drug development time line is included.
openaire   +2 more sources

The Drug Regulatory System of the United States Food and Drug Administration: A Defense of Current Requirements for Safety and Efficacy [PDF]

open access: possibleInternational Journal of Health Services, 1974
The 1962 Amendments to the Food, Drug, and Cosmetic Act have substantially increased the accountability of manufacturers of new drugs, both by raising standards for clinical testing as well as requiring, for the first time, a demonstration of proof of efficacy.
openaire   +2 more sources

United States Food and Drug Administration’s Total Diet Study Program

2013
The US launched the first total diet study in 1961 and has conducted the program continuously since then. This chapter describes the evolution of the TDS methodology used in the US, with a particular emphasis on the current sampling strategy, analytical coverage, and use of the TDS results in estimating dietary exposures.
openaire   +2 more sources

Nonclinical Development of Radiopharmaceuticals: Regulatory Considerations for the United States Food and Drug Administration

2004
In general, the nonclinical studies conducted to support the development of radiopharmaceuticals should be consistent with current International Conference on Harmonization (ICH) Guidelines. The United States Food and Drug Administration (FDA), however, has recognized that certain characteristics of radiopharmaceuticals necessitate an adaptation of the
openaire   +3 more sources

Automatic External Defibrillators and the United States Food and Drug Administration: An Invited Commentary

Annals of Emergency Medicine, 1995
Abstract [Burlington DB: Automatic external defibrillators and the United States Food and Drug Administration: An invited commentary. Ann Emerg Med November 1995;26:632-634.]
openaire   +2 more sources

Update on regulatory review intervals for ophthalmic new drug applications at the United States Food and Drug Administration

American Journal of Ophthalmology, 2000
To update the analysis of the regulatory review interval for ophthalmic new drug applications at the United States Food and Drug Administration for the years 1997 to 1999, based on the previous review by the author of the period 1990 to 1996.Publicly available records on ophthalmic drugs approved by the Food and Drug Administration in this time period ...
openaire   +3 more sources

Home - About - Disclaimer - Privacy